Skip to main content

Manufacturing Market Continuous by Roots Analysis

 

 

Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030.”

 

The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing

§  Elaborate profiles of some of the key contract manufacturers active in the pharmaceutical and biopharmaceutical continuous manufacturing market

§  An analysis of the various partnerships related to continuous manufacturing, which have been established since 2013

§  An analysis of the expansions related to continuous manufacturing, which have been established since 2013

§  An estimate of the global, continuous manufacturing capacity, based on the capacities of various industry stakeholders (as available on their respective company websites).

§  A study of the various grants that have been awarded to research institutes engaged in projects related to continuous manufacturing, between 2014 and 2019

§  An in-depth analysis of the various patents that have been filed / granted related to continuous manufacturing till 2019

§  Initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.

§  A review of the companies offering modular facilities / modular cleanrooms

§  A case study of the companies offering technologies / equipment

§  A case study on the roadmap for the adoption of continuous manufacturing technique

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Purpose of Manufacturing

§  In-House

§  Contract service

§  Scale of Operation

§  Commercial

§  Preclinical / Clinical

§  Type of Continuous Manufacturing related Service

§  API Manufacturing

§  End Product manufacturing

§  Type of Drug Molecule

§  Biologic

§  Small Molecule

§  Type of dosage form

§  Solid

§  Liquid

§  Key Geographical Regions

§   North America

§   Europe

§   Asia Pacific

To Request for sample report - https://www.rootsanalysis.com/reports/308/request-sample.html

 

§  Transcripts of interviews held with the following senior level representatives of stakeholder companies

§  Andrea Adamo, Founder and Chief Executive Officer, Zaiput Flow technologies

§  Bayan Takizawa, Co-Founder and Chief Business Officer, CONTINUUS Pharmaceuticals

§  Nick Thomson, Senior Director Chemical Research and Development, Pfizer

§  Himanshu Gadgil, Director and Chief Scientific Officer, Enzene Biosciences

§  Eric Fang, Chief Scientific Officer, Snapdragon Chemistry)

§  Ian Houson, Technical Project Manager, Continuous Manufacturing and Crystallization, University of Strathclyde

 

Key companies covered in the report

§  AbbVie Contract Manufacturing

§  Ajinomoto Bio-Pharma Services

§  Almac

§  Boehringer Ingelheim BioXcellence

§  Cambrex

§  CordonPharma

§  Hovione

§  Kaneka

§  Lonza

§  Patheon

§  SK biotek

§  WuXi AppTec

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/continuous-manufacturing/308.html

 

Other Offerings

1.     Pharmaceutical Contract Manufacturing Market (2nd Edition), 2018-2028

2.     Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030

3.     China Pharmaceutical Contract Manufacturing Services Market, 2020-2030

4.     China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

 

Comments

Post a Comment

Popular posts from this blog

The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis

  Roots Analysis has announced the addition of “ Gene Therapy Market (4th Edition), 2020-2030” report to its list of offerings.   Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.   To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights   Around 800 gene therapies are currently being developed across different stages Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of developmen...
Post a Comment
Read more

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

  Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways ”.   The   report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of ...
Post a Comment
Read more

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.

  Key Inclusions §   A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities. §   A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs. §   A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China. §   Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of p...
Post a Comment
Read more